Disease modifying
therapies compromise immune response to SARS-Cov2 or its
vaccine in patients with
immune system diseases (ISD). Therefore, analysis of the humoral and cellular responses against Spike is of utmost importance to manage ISD patients. A single-center retrospective study was conducted to evaluate the impact of
COVID-19 immunization in 87 ISD patients and 81 healthy controls. We performed a whole blood
interferon gamma release assay using SARS-Cov2 Spike and Nucleocapsid
recombinant proteins in order to evaluate T-cell memory response, and an
IgG anti-Spike ELISA to evaluate humoral response. Cellular (26.4%) and humoral (44.8%) responses were negative against Spike in ISD patients following
COVID-19 immunization. In univariate analysis, an anti-Spike T cell defective response was associated with the use of
glucocorticoids (Odds ratio [OR] = 10.0; p < 10-4),
serum albumin level ≤40 g/L (OR = 18.9; p < 10-4), age over 55 years old (OR = 3.9, p = 0.009) and ≤2
vaccine injections (OR = 4.9; p = 0.001). The impact of
glucocorticoids persisted after adjustment for age and number of
vaccine injections (OR = 8.38, p < 0.001). In contrast, the humoral response was impacted by the use of anti-CD20 mAb (OR = 24.8, p < 10-4), and an extended time since immunization (≥75 days; OR = 4.3, p = 0.002). Double defective cellular/humoral responses (6.9%) were typically encountered in
glucocorticoids and/or anti-CD20 mAb treated ISD with a
serum albumin level ≤40 g/L (OR = 17.5; p = 0.002).
Glucocorticoid usage, B cell depleting
therapies, and a low
serum albumin level were the main factors associated with a non-response to
COVID-19 immunization in ISD patients. These results need further confirmation in larger studies.